Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol
dc.contributor.author | Gooding, Kim M. | |
dc.contributor.author | Lienczewski, Chrysta | |
dc.contributor.author | Papale, Massimo | |
dc.contributor.author | Koivuviita, Niina | |
dc.contributor.author | Maziarz, Marlena | |
dc.contributor.author | Dutius Andersson, Anna-Maria | |
dc.contributor.author | Sharma, Kanishka | |
dc.contributor.author | Pontrelli, Paola | |
dc.contributor.author | Garcia Hernandez, Alberto | |
dc.contributor.author | Bailey, Julie | |
dc.contributor.author | Tobin, Kay | |
dc.contributor.author | Saunavaara, Virva | |
dc.contributor.author | Zetterqvist, Anna | |
dc.contributor.author | Shelley, David | |
dc.contributor.author | Teh, Irvin | |
dc.contributor.author | Ball, Claire | |
dc.contributor.author | Puppala, Sapna | |
dc.contributor.author | Ibberson, Mark | |
dc.contributor.author | Karihaloo, Anil | |
dc.contributor.author | Metsärinne, Kaj | |
dc.contributor.author | Banks, Rosamonde E. | |
dc.contributor.author | Gilmour, Peter S. | |
dc.contributor.author | Mansfield, Michael | |
dc.contributor.author | Gilchrist, Mark | |
dc.contributor.author | de Zeeuw, Dick | |
dc.contributor.author | Heerspink, Hiddo J. L. | |
dc.contributor.author | Nuutila, Pirjo | |
dc.contributor.author | Kretzler, Matthias | |
dc.contributor.author | Welberry Smith, Matthew | |
dc.contributor.author | Gesualdo, Loreto | |
dc.contributor.author | Andress, Dennis | |
dc.contributor.author | Grenier, Nicolas | |
dc.contributor.author | Shore, Angela C. | |
dc.contributor.author | Gomez, Maria F. | |
dc.contributor.author | Sourbron, Steven | |
dc.date.accessioned | 2022-08-10T18:11:23Z | |
dc.date.available | 2022-08-10T18:11:23Z | |
dc.date.issued | 2020-06-29 | |
dc.identifier.citation | BMC Nephrology. 2020 Jun 29;21(1):242 | |
dc.identifier.uri | https://doi.org/10.1186/s12882-020-01901-x | |
dc.identifier.uri | https://hdl.handle.net/2027.42/173568 | en |
dc.description.abstract | Abstract Background Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes. DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these have modest value for predicting future renal status. There is an unmet need for biomarkers that can be used in clinical settings which also improve prediction of renal decline on top of routinely available data, particularly in the early stages. The iBEAt study of the BEAt-DKD project aims to determine whether renal imaging biomarkers (magnetic resonance imaging (MRI) and ultrasound (US)) provide insight into the pathogenesis and heterogeneity of DKD (primary aim) and whether they have potential as prognostic biomarkers in DKD (secondary aim). Methods iBEAt is a prospective multi-centre observational cohort study recruiting 500 patients with type 2 diabetes (T2D) and eGFR ≥30 ml/min/1.73m2. At baseline, blood and urine will be collected, clinical examinations will be performed, and medical history will be obtained. These assessments will be repeated annually for 3 years. At baseline each participant will also undergo quantitative renal MRI and US with central processing of MRI images. Biological samples will be stored in a central laboratory for biomarker and validation studies, and data in a central data depository. Data analysis will explore the potential associations between imaging biomarkers and renal function, and whether the imaging biomarkers improve the prediction of DKD progression. Ancillary substudies will: (1) validate imaging biomarkers against renal histopathology; (2) validate MRI based renal blood flow measurements against H2O15 positron-emission tomography (PET); (3) validate methods for (semi-)automated processing of renal MRI; (4) examine longitudinal changes in imaging biomarkers; (5) examine whether glycocalyx and microvascular measures are associated with imaging biomarkers and eGFR decline; (6) explore whether the findings in T2D can be extrapolated to type 1 diabetes. Discussion iBEAt is the largest DKD imaging study to date and will provide valuable insights into the progression and heterogeneity of DKD. The results may contribute to a more personalised approach to DKD management in patients with T2D. Trial registration Clinicaltrials.gov ( NCT03716401 ). | |
dc.title | Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol | |
dc.type | Journal Article | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/173568/1/12882_2020_Article_1901.pdf | |
dc.identifier.doi | https://dx.doi.org/10.7302/5299 | |
dc.language.rfc3066 | en | |
dc.rights.holder | The Author(s) | |
dc.date.updated | 2022-08-10T18:11:23Z | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.